Liquidia Corporation (FRA:LT4)

Market Cap	2.48B +94.0%
Revenue (ttm)	58.99M +343.4%
Net Income	-105.76M
EPS	-1.24
Shares Out	n/a
PE Ratio	n/a
Forward PE	14.32
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	55
Open	29.42
Previous Close	29.36
Day's Range	29.42 - 29.42
52-Week Range	10.08 - 39.28
Beta	n/a
RSI	37.67
Earnings Date	Mar 16, 2026

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational ...

• Industry: Pharmaceutical Preparations
• Founded: 2004
• Employees: 170
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LT4

Financial Performance

In 2024, Liquidia's revenue was $14.00 million, a decrease of -19.97% compared to the previous year's $17.49 million. Losses were -$130.39 million, 66.1% more than in 2023.

Financial numbers in USD